Evidence map›Paper›PMID 26322947›Full record

ArticlePloS one2015

Differential Expression of Specific Dermatan Sulfate Domains in Renal Pathology.

Joost F M Lensen, Johan van der Vlag, Elly M M Versteeg, Jack F M Wetzels, Lambert P W J van den Heuvel, Jo H M Berden, Toin H van Kuppevelt, Angelique L W M M Rops

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Joost F M LensenDepartment of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Johan van der VlagNephrology Research Laboratory, Radboud Institute for Molecular Life Sciences, Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
Elly M M VersteegDepartment of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Jack F M WetzelsNephrology Research Laboratory, Radboud Institute for Molecular Life Sciences, Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
Lambert P W J van den HeuvelDepartment of Pediatrics, Radboud University Medical Center, Nijmegen, The Netherlands.
Jo H M BerdenNephrology Research Laboratory, Radboud Institute for Molecular Life Sciences, Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
Toin H van KuppeveltDepartment of Biochemistry, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Angelique L W M M RopsNephrology Research Laboratory, Radboud Institute for Molecular Life Sciences, Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
Radboud University Medical Center · NLRadboud University Nijmegen · NLRadboud Institute for Molecular Life Sciences · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dermatan sulfate (DS), also known as chondroitin sulfate (CS)-B, is a member of the linear polysaccharides called glycosaminoglycans (GAGs). The expression of CS/DS and DS proteoglycans is increased in several fibrotic renal diseases, including interstitial fibrosis, diabetic nephropathy, mesangial sclerosis and nephrosclerosis. Little, however, is known about structural alterations in DS in renal diseases. The aim of this study was to evaluate the renal expression of two different DS domains in renal transplant rejection and glomerular pathologies. DS expression was evaluated in normal renal tissue and in kidney biopsies obtained from patients with acute interstitial or vascular renal allograft rejection, patients with interstitial fibrosis and tubular atrophy (IF/TA), and from patients with focal segmental glomerulosclerosis (FSGS), membranous glomerulopathy (MGP) or systemic lupus erythematosus (SLE), using our unique specific anti-DS antibodies LKN1 and GD3A12. Expression of the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 was decreased in the interstitium of transplant kidneys with IF/TA, which was accompanied by an increased expression of type I collagen, decorin and transforming growth factor beta (TGF-β), while its expression was increased in the interstitium in FSGS, MGP and SLE. Importantly, all patients showed glomerular LKN1 staining in contrast to the controls. Expression of the IdoA-Gal-NAc4SDS domain recognized by GD3A12 was similar in controls and patients. Our data suggest a role for the DS domain recognized by antibody LKN1 in renal diseases with early fibrosis. Further research is required to delineate the exact role of different DS domains in renal fibrosis.

Indexed as

AdolescentAdultAgedChild, PreschoolCollagen Type IDermatan SulfateFemaleGraft RejectionHumansKidneyKidney DiseasesKidney TransplantationMaleMiddle AgedTransforming Growth Factor betaYoung AdultCollagen Type IDermatan SulfateTransforming Growth Factor beta

Identifiers

PMID26322947
PMCPMC4556443
OpenAlexW1781117934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.